Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Xiaofei Jiao

Tongji Hospital

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 10, 2026 · JOURNAL ARTICLE

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

Advanced Science

Preclinical mechanistic study in immunocompetent mice with engineered CAR-T cells, informing an ongoing Phase 1 trial; no human efficacy or safety data reported.

PreliminaryYong Fang Minghua Xiang CAR-T Cell Therapy Research

Study details

DesignPreclinical in vivo study in immunocompeten…

InterventionNiraparib (PARP inhibitor) plus anlotinib (…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support